CN1698775A - Pharmaceutical composition containing lamivudine - Google Patents
Pharmaceutical composition containing lamivudine Download PDFInfo
- Publication number
- CN1698775A CN1698775A CNA200510069896XA CN200510069896A CN1698775A CN 1698775 A CN1698775 A CN 1698775A CN A200510069896X A CNA200510069896X A CN A200510069896XA CN 200510069896 A CN200510069896 A CN 200510069896A CN 1698775 A CN1698775 A CN 1698775A
- Authority
- CN
- China
- Prior art keywords
- lamivudine
- group
- pharmaceutical composition
- herba artemisiae
- artemisiae scopariae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 title claims abstract description 43
- 229960001627 lamivudine Drugs 0.000 title claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 claims description 7
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 6
- 229930003944 flavone Natural products 0.000 claims description 5
- 235000011949 flavones Nutrition 0.000 claims description 5
- 229930193195 schizandrin Natural products 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 150000002213 flavones Chemical class 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000005457 optimization Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 abstract description 14
- 208000002672 hepatitis B Diseases 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 42
- 229940079593 drug Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 230000000242 pagocytic effect Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 229940124531 pharmaceutical excipient Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 241000272525 Anas platyrhynchos Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000013641 positive control Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000167854 Bourreria succulenta Species 0.000 description 5
- 235000019693 cherries Nutrition 0.000 description 5
- 241000725618 Duck hepatitis B virus Species 0.000 description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000002279 cholagogic effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229940098312 lamivudine 100 mg Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 description 2
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- IZWKTABKAJGBFW-UHFFFAOYSA-N arcapillin Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(OC)=C(OC)C(O)=C3C(=O)C=2)=C1O IZWKTABKAJGBFW-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- -1 coumarin, flavone Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
- RNKMOGIPOMVCHO-SJMVAQJGSA-N 1,3,6-trigalloyl glucose Chemical compound C([C@@H]1[C@H]([C@@H]([C@@H](O)[C@H](OC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 RNKMOGIPOMVCHO-SJMVAQJGSA-N 0.000 description 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000272522 Anas Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- YLEQMGZZMCJKCN-NKWVEPMBSA-N [[(2r,5s)-5-(4-amino-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)SC1 YLEQMGZZMCJKCN-NKWVEPMBSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229960003764 polydatin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930192961 schisandrol Natural products 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition containing lamivudine, which is prepared from the following materials, giant knotweed rhizome 50-300 weight parts, oriental wormwood 0-300 weight parts, schisandra chinensis 0-400 weight parts, Lamivudine 20-300 weight parts. The composition can be used for treating hepatitis B disease and effectively inhibiting HBV virus.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of hepatitis B, specifically a kind of Chinese medicine pharmaceutical composition that contains lamivudine.
Background technology
It is a serious global health problem that chronic HBV (HBV) infects, and the whole world has 3.5 hundred million people to infect hepatitis B virus for a long time approximately according to estimates.And China is the district occurred frequently of viral hepatitis, and the average year sickness rate is about about 2,000,000, has data to show that about at present 1.2 hundred million people of China carry HBV virus.Medicine how to develop the treatment hepatitis B of determined curative effect has become China medicine scholar key task.Clearly emphasize in the Ministry of Science and Technology, State Administration of Traditional Chinese Medicine's key subjects " research of traditional Chinese medical science modernization science and technology development strategy " should " emphasis carries out the traditional Chinese medical science to be duplicated, regulates immunologic function, alleviate hepatocyte injury, improves liver function hepatitis B virus antiviral, especially traditional Chinese medical science anti-hepatic fibrosis, prevent and treat early stage cirrhotic curative effect and Integrated Program Study.”
The treatment of hepatitis B is often based on the antiviral therapy medicine at present, and as interferon, nucleoside analog etc., but curative effect is all unsatisfactory.The antiviral drugs lamivudine that clinical practice is the widest duplicates though it can effectively suppress hepatitis B virus (HBV) fast, and whole curative effect is also well below people's Expected Results.Especially after its side effect, the drug withdrawal relapse rate high and easily cause virus variation disadvantages affect this drug use.Chinese medicine demonstrates comparatively clear superiority by contrast.Experimentation proves, a lot of Chinese herbal medicine or the specially square very curative effect of uniqueness that truly has, for example, Rhizoma Polygoni Cuspidati extract, chlorogenic acid in the Herba Artemisiae Scopariae, coumarin, flavone, polyporusum bellatuss in schisandrin B in matrine in the Radix Sophorae Flavescentis and oxymatrine, the Fructus Schisandrae Chinensis (bifendate), the Polyporus etc. show preferable curative effect at aspects such as antiviral, immunomodulating, hepatic cholagogic, transaminase lowering.But Chinese medicine is bigger because of taking dose, takes effect slowly, and the cycle is long, and the problem of can not fine control medicine effect one-tenth grading is difficult to satisfy people's requirement.
Integrative Chinese-Western is used day by day extensive clinically in recent years, especially at anti-AIDS, tumor, the cardiovascular diseases, influenza, hepatitis, aspects such as gastropathy, its therapeutic effect often is better than single Drug therapy, and SARS storm in 2003 makes the advantage of Chinese medicine and western medicine coupling cause that the world attractes attention, and has also caused that Chinese and western medical circle pays much attention to and unprecedented common recognition simultaneously.National Drug Administration is also to this great attention, and be about to put into effect relevant policies and regulations, the compound preparation that additional Chinese medicine adds the Western medicine joint development is the 4th a kind of new drug of Chinese medicine registration classification the 6th apoplexy due to endogenous wind. therefore, the present invention adopts advanced science and technology to Chinese medicine Rhizoma Polygoni Cuspidati, Herba Artemisiae Scopariae, Fructus Schisandrae Chinensis and Western medicine lamivudine comprehensive development and utilization in addition, adopt combinational therapeutic methods, scientific composition is developed into safe, efficient, controlled, stable, the novel Chinese medicine and western medicine compound preparation easily of treatment hepatitis B diseases with it.
Summary of the invention
The purpose of this invention is to provide a kind of compound preparation for the treatment of chronic viral hepatitis B, this medicine not only has and efficiently suppresses the HBV virus function rapidly, reduce glutamate pyruvate transaminase (ALT) level fast, improve patient's jaundice symptom and hepatic cholagogic, adjusting immunity in addition, reduce the HBV virus variation, recover the generation of liver function and prevention hepatic fibrosis.
Purpose of the present invention can take following method to realize:
A kind of pharmaceutical composition that contains lamivudine is characterized in that it is that component is formed or made active component and pharmaceutically acceptable additives are formed or make active component and pharmaceutically acceptable additives are formed by the alcohol extract of following main materials by the water extract of following main materials by following main materials:
Rhizoma Polygoni Cuspidati 50-300 weight portion, Herba Artemisiae Scopariae 0-300 weight portion, Fructus Schisandrae Chinensis 0-400 weight portion, lamivudine 20-300 weight portion.
It is characterized in that formula optimization is: Rhizoma Polygoni Cuspidati 200 weight portions, Herba Artemisiae Scopariae 150 weight portions, Fructus Schisandrae Chinensis 300 weight portions, lamivudine 100 weight portions.
Its dosage form can be said dosage form on any pharmaceutics, for example capsule, tablet, granule, oral liquid, drop pill, aqueous injection or injectable powder.
Described Fructus Schisandrae Chinensis is schizandrin or deoxyschizandrin.
Described Herba Artemisiae Scopariae is a Herba Artemisiae Scopariae total flavones.
Also comprise polidatin 20-300 weight portion.
Compound preparation of the present invention adopts the composition of medicine of lamivudine and some Chinese medicine extract to treat chronic hepatitis B just.The Chinese medicine extract that the present invention screened is respectively: Rhizoma Polygoni Cuspidati extract, Herba Artemisiae Scopariae extract, Fructus Schisandrae Chinensis extrat.Below be introduction to these materials:
Lamivudine (Lamivudine) is to have the powerful nucleoside medicine of new generation that suppresses the multiple effect of virus.After being used for the treatment of HIV, state Drug Administration and U.S. FDA will be ratified this medicine again in the end of the year 1998 and are used to treat chronic hepatitis B.Its chemistry (2R-cis)-4-amino-1-(2-methylol-1,3-oxygen thia ring penta-5-yl) pyrimid-2-one by name, molecular formula is C
8H
11N
3O
3S; molecular weight is 229; lamivudine can generate the lamivudine triphosphate at HBV infection cell and normal cell intracellular metabolite; the biological activity of the DNA polymerase by reducing the HBV dependenc RNA suppresses the synthetic of HBVDNA, reduces the hepatocellular copy number of getting involved; and by reversing the low reaction state of body T cell; recover the T cytoactive, the protection normal liver cell impels the hepatocellular upset of getting involved simultaneously.Blocking virus DNA's is synthetic, suppresses hbv replication rapidly, and its inhibitory action is sustainable in whole therapeutic process.
Rhizoma Polygoni Cuspidati extract extracts from the Polygonaceae Rhizoma Polygoni Cuspidati, and its effective ingredient mainly is compositions such as anthraquinone class, flavonoid, polydatin, water soluble polysaccharide and tannin.Its anthraquinone analog compound Radix Et Rhizoma Rhei have strong antivirus action; Basic Experiment Study also proves; Rhizoma Polygoni Cuspidati extract all has the good restraining effect to DHB (DHBV) and hepatitis B virus (HBV); and can increase the liver function blood flow; promote hepatocyte to repair and regeneration, reach the effect of protection hepatic injury.Tannin composition wherein can also improve macrophage phagocytic function, the immunoregulation capability of enhancing body.
Herba Artemisiae Scopariae extract extracts from the Chinese medicine Herba Artemisiae Scopariae, effective ingredient mainly contains arcapillin, chlorogenic acid, Quercetin, isorhamnetin and Herba Artemisiae Scopariae water soluble polypeptide etc., Herba Artemisiae Scopariae extract can make the hepatocyte vigor obviously improve, want good hepatoprotective effect, Herba Artemisiae Scopariae can also the quick jaundice eliminating of clearing away heat-damp and promoting diuresis in addition, effectively remove jaundice symptom, the effect of removing that tool is stronger simultaneously and inhibition ultra-oxygen anion free radical, hepatocyte lipid peroxidation capable of blocking, suppress the hepatic tissue fibronectin and express the effect that alleviates degree of hepatic fibrosis.
Fructus Schisandrae Chinensis extrat extracts from the Chinese medicine Fructus Schisandrae Chinensis, and effective ingredient mainly contains schizandrin, deoxyschizandrin, schisandrin B, schisandrin and schisandrol the second grade, and wherein the molecular formula of deoxyschizandrin is C
24H
32O
6Fructus Schisandrae Chinensis extrat has significant hepatocyte injury antagonism, block of the damage of multiple virus to liver plasma membrane, and can effectively reduce glutamate pyruvate transaminase (ALT) level, regulate T lymphocyte differentiation, ripe autoimmune stable to keep, can strengthen liver detoxification function, help the hepatocyte function reparation.
Compound preparation of the present invention designs with the differentiation of tcm theoretical direction, adopt scientific composition, lamivudine is effectively made up with relevant Chinese medicine extract, combine the advantage of Chinese medicine and Western medicine, the effect of performance synergistic corrosion virus remedies the not enough point of single medication again mutually, carry out many target spots at hepatitis B diseases jointly, multi-angle, multi-level treatment.Compound preparation of the present invention has following positive effectiveness: effectively suppress HBV virus, reduce glutamate pyruvate transaminase (ALT) level fast, improve jaundice symptom, hepatic cholagogic, reduce the HBV virus variation, regulate immunity of organism, recover the generation of liver function and prevention and reverse hepatic fibrosis.
The specific embodiment
Describe implementation of the present invention in detail below in conjunction with embodiment.
Embodiment 1:
Rhizoma Polygoni Cuspidati water extract 200mg,
Herba Artemisiae Scopariae water extract 150mg,
Fructus Schisandrae Chinensis water extract 300mg,
Lamivudine 100mg.
Make capsule, tablet, granule, oral liquid etc. by above-mentioned prescription according to the method for producing medicines interpolation proper pharmaceutical excipients of prior art.
Embodiment 2:
Rhizoma Polygoni Cuspidati water extract 200mg,
Fructus Schisandrae Chinensis water extract 300mg,
Lamivudine 100mg.
Make capsule, tablet, granule, oral liquid etc. by above-mentioned prescription according to the method for producing medicines interpolation proper pharmaceutical excipients of prior art.
Embodiment 3:
Rhizoma Polygoni Cuspidati water extract 200mg,
Fructus Schisandrae Chinensis water extract 300mg,
Lamivudine 100mg.
Make capsule, tablet, granule, oral liquid etc. by above-mentioned prescription according to the method for producing medicines interpolation proper pharmaceutical excipients of prior art.
Embodiment 4:
Polidatin 100mg,
Herba Artemisiae Scopariae total flavones 100mg,
Deoxyschizandrin 50mg,
Lamivudine 50mg.
Make lyophilized injectable powder, aqueous injection or oral liquid by above-mentioned prescription according to the method for producing medicines interpolation proper pharmaceutical excipients of prior art.
Embodiment 5:
Polidatin 100mg,
Schizandrin 80mg,
Lamivudine 50mg.
Make lyophilized injectable powder, aqueous injection or oral liquid by above-mentioned prescription according to the method for producing medicines interpolation proper pharmaceutical excipients of prior art.
Embodiment 6:
Rhizoma Polygoni Cuspidati alcohol extract 300mg,
Lamivudine 50mg.
Make capsule, tablet, granule, oral liquid etc. by above-mentioned prescription according to the method for producing medicines interpolation proper pharmaceutical excipients of prior art.
Embodiment 7:
Schizandrin 80mg,
Lamivudine 50mg.
Make capsule, tablet, granule, oral liquid etc. by above-mentioned prescription according to the method for producing medicines interpolation proper pharmaceutical excipients of prior art.
Embodiment 8:
Rhizoma Polygoni Cuspidati alcohol extract 300mg,
Deoxyschizandrin 50mg,
Lamivudine 50mg.
Make capsule, tablet, granule, oral liquid etc. by above-mentioned prescription according to the method for producing medicines interpolation proper pharmaceutical excipients of prior art.
Embodiment 9:
Rhizoma Polygoni Cuspidati alcohol extract 200mg,
Herba Artemisiae Scopariae total flavones 100mg,
Deoxyschizandrin 50mg,
Lamivudine 50mg.
Make capsule, tablet, granule, oral liquid etc. by above-mentioned prescription according to the method for producing medicines interpolation proper pharmaceutical excipients of prior art.
Several main animal experiments contrasts select lamivudine group, Rhizoma Polygoni Cuspidati extract group for use, fill a prescription one group (Rhizoma Polygoni Cuspidati extract+Herba Artemisiae Scopariae extract+Fructus Schisandrae Chinensis extrat+lamivudine) carrying out, its experimental result is as follows:
Experimental example 1:
To CCl
4Cause the influence of Serum ALT in the mouse liver injury, AST
1, experimental technique:
Mice is divided into 5 groups at random, 15 every group.Design lamivudine group, Rhizoma Polygoni Cuspidati extract group, one group of three matched group of prescription are established the dosage group by 10 times of human body recommended amounts, and 0.25g/kg is assigned to desired concn with capsule 's content with distilled water; Establish blank group and CCl in addition
4Positive controls.Five dosage groups are irritated stomach by 0.02ml/g body weight per os and are tried thing; Blank group and CCl
4Positive controls gives distilled water.Animal weighs twice weekly, is tried the agent amount with adjustment, and free diet drinking-water is in testing the 30th day with each treated animal fasting overnight 16 hours.CCl
4Positive controls and each dosage treated animal are irritated the CCl that stomach gives 32mg/kg 1 time by the 0.01ml/g body weight
4Contamination is a solvent with the refined maize oil; The blank group gives Semen Maydis oil 32mg/kg; Respectively be subjected to examination group CCl
4Contaminate and continue to give given the test agent after 4 hours.Give CCl
4Pluck eyeball after 24 hours and get blood, separation of serum is measured ALT, AST, puts to death animal simultaneously.
2, experimental result: CCl
4The ALT of positive controls mice, AST content are than blank group height, and through the T check, difference has significance (P＜0.05).ALT value, AST value and CCl that lamivudine group, Rhizoma Polygoni Cuspidati extract group, prescription are one group
4Positive controls more all has decline, and through variance analysis, difference all is significance (P＜0.05).Mice is through CCl in this experiment
4After the contamination, CCl
4Hepatocyte large tracts of land necrosis around the matched group central vein, Serum ALT, AST increase greatly, show mice CCl
4The success of hepatocyte injury model copy.Though experimental group hepatic necrosis degree and Serum ALT, AST are higher than the blank group, than CCl
4The matched group pathological changes obviously alleviates, and difference has significance by statistics, illustrate the prescription one group than lamivudine group, Rhizoma Polygoni Cuspidati extract group hepatic injury has more protective effect to the CCl4 induced mice.The results are shown in Table 1.
Table 1 is respectively organized mice ALT, AST assay (x ± s)
| Group | Dosage (g/kg) | Number of animals (only) | ????ALT(U/L) ? | ????AST(U/L) ? |
| The blank group | ??- | ??15 | ??40±14.0* | ??178.5±13.7* |
| Model group | ??- | ??15 | ??1728.7±1277.0 | ??795.1±496.6 |
| Lamivudine group | ??0.06 | ??15 | ??702.5±568.2* | ??293.4±302.0* |
| The Rhizoma Polygoni Cuspidati extract group | ??0.12 | ??15 | ??617.9±695.1* | ??285.9±237.0* |
| Fill a prescription one group | ??0.25 | ??15 | ??568.3±643.3* | ??266.3±252.0* |
* represent and CCl
4Positive controls compares, P＜0.05
Experimental example 2:
DHBV is infected the influence of cherry valley duck serum DHBV-DNA:
1, experimental technique: the cherry valley duck duckling is divided into 5 groups at random, 7 every group.Infecting the cherry valley duck duckling with DHBV, after infection the 13rd day was the 5th day (P5) after (T0) before the medication, medication the 7th day (T7), medication the 14th day (T14) and the drug withdrawal, got blood from duck lower limb shin vein, separation of serum, and-70 ℃ of preservations are to be checked.
2, experimental result: cherry valley duck infects back 14 days serum DHBV-DNA total positiveses.In whole experiment, the clear DHBV-DNA level of normal saline matched group Sanguis Anas domestica does not have obvious fluctuation, (P＞0.05).1 group of lamivudine group, Rhizoma Polygoni Cuspidati extract group, prescription are still compared with the normal saline matched group before T7, T14 and administration, can both and the significant DHBV-DNA (P＜0.001) that reduces; The results are shown in Table 2.
Table 2: to the inhibitory action assay of cherry valley duck DHBV-DNA (mean ± sd)
| Group | Duck is only counted n/ | The A value | |||
| ???????T0 | ???????T7 | ???????T14 | ????????P5 | ||
| The blank group | ????7 | ??0.91±0.39 | ??0.90±0.36 | ??0.86±0.31 | ??0.84±0.34 |
| The virus control group | ????7 | ??1.57±0.43 | ??1.19±0.31 | ??1.30±0.37 | ??1.09±0.21 |
| Lamivudine group | ????7 | ??1.67±0.2 | ??0.67±0.23*# | ??0.79±0.07*# | ??0.86±0.23 |
| The Rhizoma Polygoni Cuspidati extract group | ????7 | ??1.53±0.2 | ??0.61±0.32 | ??0.73±0.25 | ??1.00±0.19 |
| Fill a prescription 1 group | ????7 | ??1.62±0.1 | ??0.58±0.49**# | ??0.62±0.45*# | ??0.7±0.62* |
(T0) A value comparison * P＜0.05 before different time after the administration (T7, T14) and drug withdrawal (P5) A value (hybridization spot light absorption value) and the administration on the same group, * * P＜0.01; Compare with the virus group: #P＜0.05, ##P＜0.01.
Experimental example 3:
Influence to the peritoneal macrophage phagocytic function:
1, experimental technique: mice is divided into 5 groups at random, 10 every group.Design lamivudine group, Rhizoma Polygoni Cuspidati extract group, one group of three matched group of prescription are established blank group and model control group in addition.The oral tap water 0.2ml/d/ of blank group and model control group is only. and other three experimental grouies are gastric infusion respectively, each organized successive administration 5 days, the 4th, 5 days, other each groups are subcutaneous injection hydroprednisone acetate (prednisolone) 5mg/kg (0.1ml/ only) except that the blank group, and other each groups all at the 4th day lumbar injection sterilization glycogen 2ml/ only except that the blank group.Put to death mice with ethanol intracranial injection method, hank ' the s liquid 2ml for preparing is injected mouse peritoneal, gently rub abdominal part 60 times, make hank ' s liquid thorough washing abdominal cavity,, again abdominal part is cut off an aperture so that obtain more macrophage, draw the interior washing liquid of abdomen in test tube, only stay 0.6ml at last, splash into 2 chicken erythrocyte suspensions and put into 0.4cm length, the wide little glass bar of 0.2cm is in test tube, 37 ℃ of water-baths were cultivated 30 minutes, shook once every 10 minutes, take out glass bar, with PBS washing 3 times, make its natural drying, methanol is fixed 8 minutes, dyes 15 minutes with Ji's nurse Sa dye liquor, with tap water flushing 3 times, behind the natural drying, 100 cells of meter under high power lens, the macrophage number of chicken red blood cell and the chicken red blood cell of being engulfed wherein engulfed in record, calculates phagocytic rate.
2, experimental result: from following table as can be seen, no matter model control group is that phagocytic percentage or phagocytic index all are lower than the blank group, illustrates that the injection hormone can make mouse peritoneal phagocyte phagocytic function descend.
Lamivudine group, Rhizoma Polygoni Cuspidati extract group, one group of three matched group phagocytic percentage of prescription and phagocytic index, all be higher than model control group, data show, lamivudine group, Rhizoma Polygoni Cuspidati extract group, prescription have the effect of the Turnover of Mouse Peritoneal Macrophages of raising phagocytic function for one group. with lamivudine group, Rhizoma Polygoni Cuspidati extract group relatively, one group the nonspecific immunity potentiation of filling a prescription is slightly high.The results are shown in Table 3.
Table 3: to the influence of peritoneal macrophage phagocytic function
| Group | Dosage | Number of animals (only) | Phagocytic percentage X ± SD (%) | Phagocytic index X ± SD |
| The blank group | ??- | ????10 | ????49.4±7.78 | ????0.835±0.186 |
| Model group | ??0.5mg/kg | ????10 | ????19.1±5.26 | ????0.238±0.127 |
| Lamivudine group | ??0.1g/kg | ????10 | ????29.7±6.99 | ????0.334±0.09* |
| The Rhizoma Polygoni Cuspidati extract group | ??0.2g/kg | ????10 | ????35.0±10.9* | ????0.423±0.158* |
| Fill a prescription one group | ??0.25g/kg | ????10 | ????37.0±15.2** | ????0.477±0.295* |
Each group compares with model group: * P＜0.05, * * P＜0.01
Claims (7)
1, a kind of pharmaceutical composition that contains lamivudine is characterized in that it is that component is formed or made active component and pharmaceutically acceptable additives are formed or make active component and pharmaceutically acceptable additives are formed by the alcohol extract of following main materials by the water extract of following main materials by following main materials:
Rhizoma Polygoni Cuspidati 50-300 weight portion, Herba Artemisiae Scopariae 0-300 weight portion, Fructus Schisandrae Chinensis 0-400 weight portion, lamivudine 20-300 weight portion.
2, the pharmaceutical composition that contains lamivudine according to claim 1 is characterized in that formula optimization is: Rhizoma Polygoni Cuspidati 200 weight portions, Herba Artemisiae Scopariae 150 weight portions, Fructus Schisandrae Chinensis 300 weight portions, lamivudine 100 weight portions.
3, the pharmaceutical composition that contains lamivudine according to claim 1 is characterized in that: its dosage form can be said dosage form on any pharmaceutics, for example capsule, tablet, granule, oral liquid, drop pill, aqueous injection or injectable powder.
4, the pharmaceutical composition that contains lamivudine according to claim 1, it is characterized in that: described Fructus Schisandrae Chinensis is a deoxyschizandrin.
5, the pharmaceutical composition that contains lamivudine according to claim 1, it is characterized in that: described Fructus Schisandrae Chinensis is a schizandrin.
6, the pharmaceutical composition that contains lamivudine according to claim 1, it is characterized in that: described Herba Artemisiae Scopariae is a Herba Artemisiae Scopariae total flavones.
7, the pharmaceutical composition that contains lamivudine according to claim 1 is characterized in that: also comprise polidatin 20-300 weight portion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510069896XA CN100457140C (en) | 2005-05-08 | 2005-05-08 | Pharmaceutical composition containing lamivudine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510069896XA CN100457140C (en) | 2005-05-08 | 2005-05-08 | Pharmaceutical composition containing lamivudine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1698775A true CN1698775A (en) | 2005-11-23 |
| CN100457140C CN100457140C (en) | 2009-02-04 |
Family
ID=35475129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200510069896XA Expired - Fee Related CN100457140C (en) | 2005-05-08 | 2005-05-08 | Pharmaceutical composition containing lamivudine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100457140C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101375842B (en) * | 2007-08-27 | 2012-08-01 | 复旦大学 | Application of lignan of biphenyl cyclooctene series in preparing anti-hepatitis B virus medicament |
| CN106692694A (en) * | 2016-12-07 | 2017-05-24 | 郑州郑先医药科技有限公司 | Japanese buttercup herb extract-containing Chinese and western medicine composition for treating liver cirrhosis and preparation method thereof |
| CN106994122A (en) * | 2016-01-26 | 2017-08-01 | 中国人民解放军军事医学科学院毒物药物研究所 | The purposes of schizandrin A anti-hepatic fibrosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2003020302A1 (en) * | 2001-08-28 | 2004-12-16 | 東レ株式会社 | Hepatitis B virus proliferation inhibitor |
| US6855346B2 (en) * | 2001-10-05 | 2005-02-15 | Tzu-Sheng Wu | Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same |
| CN1466947A (en) * | 2003-05-27 | 2004-01-14 | 杨喜鸿 | Combined medicine containing lamivudine |
-
2005
- 2005-05-08 CN CNB200510069896XA patent/CN100457140C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101375842B (en) * | 2007-08-27 | 2012-08-01 | 复旦大学 | Application of lignan of biphenyl cyclooctene series in preparing anti-hepatitis B virus medicament |
| CN106994122A (en) * | 2016-01-26 | 2017-08-01 | 中国人民解放军军事医学科学院毒物药物研究所 | The purposes of schizandrin A anti-hepatic fibrosis |
| CN106692694A (en) * | 2016-12-07 | 2017-05-24 | 郑州郑先医药科技有限公司 | Japanese buttercup herb extract-containing Chinese and western medicine composition for treating liver cirrhosis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100457140C (en) | 2009-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1907462A (en) | Traditional Chinese medicine composition for treating hepatitis and fatty liver | |
| CN100457140C (en) | Pharmaceutical composition containing lamivudine | |
| CN1434052A (en) | Cranesbill total flavonoid extract and use in preparation of anti-virus medicine | |
| CN101044857A (en) | Application of compounding preparation in medicine for treating human Aids hepatitis and skin diseases | |
| CN1296089C (en) | Zedoary injection preparation and its preparing method | |
| CN100346800C (en) | Chinese medicine composition for preventing and treating hepatitis | |
| CN1051470C (en) | Medicine for curing viral hepatitis | |
| CN1051468C (en) | Capsule for curing rheumatism | |
| CN101352486A (en) | Isatis root and astragalus microspheres for injections and preparation method thereof | |
| CN101401847A (en) | Medicament composition containing lamivudine | |
| CN1275640C (en) | Medicine for treating chromic avidity, persistent hepatitis B and its preparation method | |
| CN1590398A (en) | Preparation of gentian effective part and its application | |
| CN1251745C (en) | Medicine for treating liver and biliary diseases and its preparing method | |
| CN1281212C (en) | General saponin of stem and leaf of American ginseng in Application of preparing medication for treating mycoarditis | |
| CN1679887A (en) | Chinese medicine composition for treating hepatitis | |
| CN1237975C (en) | Application of general saponin of gen-seng fruit in the preparation process of myocarditis treating medicine | |
| CN103690552A (en) | Pharmaceutical composition and application thereof to preparing pharmaceutical preparation for treating hepatitis B | |
| CN1212150C (en) | Medicine for treating virus hepatitis and its preparation method | |
| CN101045116A (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN101057906A (en) | Traditional Chinese medicinal composition for treating hepatitis and its preparation method and medicinal preparation | |
| CN1562111A (en) | Application of the stem and leaf extract of Chimang in treating diabetes and improving its symptoms | |
| CN1466947A (en) | Combined medicine containing lamivudine | |
| CN1177592C (en) | Application of Radix Radix Radix Radix Extract Total Saponins in the Preparation of Drugs for Treating Myocarditis | |
| CN1695717A (en) | Combination of medication for treating hepatic disease, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jiangxi Zhengbang Animal Health Products Co., Ltd. Assignor: Bencao Tian'gong Science & Tech. Co., Ltd., Jiangxi Contract record no.: 2010360000023 Denomination of invention: Pharmaceutical composition containing lamivudine and preparation method and application thereof Granted publication date: 20090204 License type: Exclusive License Open date: 20051123 Record date: 20100514 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090204 Termination date: 20160508 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |